Kenvue (KVUE.US), the parent company of the pain reliever and fever reducer Tylenol, has made the most detailed defense of its flagship product, urging U.S. regulators to reject a citizen petition requesting that Tylenol be labeled with an autism association.
In documents submitted to the U.S. Food and Drug Administration (FDA) on the 17th of this month, Kenvue stated that the request to change the drug labeling lacks scientific basis and is also legally and procedurally inappropriate, with overwhelming evidence negating any claims of risk between the over-the-counter pain and fever medication and neurodevelopmental disorders

KVUE

Kenvue, the parent company of Tylenol, rebutted the U.S. regulators' demands regarding its drug labeling, stating that there is a lack of scientific basis. Kenvue pointed out in documents submitted to the FDA that the citizen petition requesting label changes is illegal and procedurally improper, and provided overwhelming evidence denying the association between Tylenol and autism risk

AASTOCKS

Kenvue

Kenvue, the parent company of Tylenol, refutes U.S. regulatory agencies' opposition to labeling regarding the use of medication during pregnancy and its association with autism risk

泰诺母企 Kenvue 反驳美监管机构 反对标签怀孕期间用药涉自闭症风险

泰诺母企 Kenvue 反驳美监管机构反对标签怀孕期间用药涉自闭症风险